Browse by category

Outcomes from the BARI-STEP trial, led by Dr Janine Makaronidis at the University College London Hospitals (UCLH) Centre for Obesity Research, has concluded that the weight loss drug semaglutide helps patients who do not respond to bariatric surgery. Janine Makaronidis “These findings strengthen the case for using semaglutide in people who do not respond well to bariatric surgery, offering an alternative to repeat operations,” said Makaronidis. “They also suggest that combini

An outpatient procedure may offer a way for the estimated 70% of people who discontinue popular weight-loss drugs to avoid regaining weight, according to a study, ‘Duodenal mucosal resurfacing prevents weight regain after tirzepatide withdrawal: REMAIN-1 multicenter, randomized, double-blind, sham-controlled clinical trial—midpoint cohort results’, presented at Digestive Disease Week 2026. Nearly one in five adults with obesity have taken a glucagon-like peptide-1 (GLP-1), an

The ForePass endoscopic metabolic bypass platform reproduced insulin sensitivity levels observed following biliopancreatic diversion (BPD) while substantially outperforming semaglutide (Ozempic/Wegovy) in weight control in a randomised preclinical study, according to a study led by Professor Ivo Boskoski, Professor of Digestive Endoscopy at Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Rome, Lazio, Italy. ForePass endoscopic metabolic bypass platform

Researchers at Cleveland Clinic have demonstrated that metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis regression can occur following metabolic and bariatric surgery (MBS). The study, “Can Metabolic Surgery Regress MASH Cirrhosis? Evidence From Paired Biopsies,” was presented at the 2026 Digestive Disease Week Annual Meeting. In a retrospective cohort of patients with biopsy-proven compensated MASH cirrhosis undergoing MBS, investigators evaluated long-term

Researchers at Lund University and AstraZeneca have reported that integrating measurements such as body fat percentage and waist circumference captures disease risks missed by BMI alone. This study provides increasing evidence for including more parameters than BMI in the diagnosis of obesity. In recent years, research has shown that there are several limitations with BMI alone when it comes to assessing adiposity quantity, distribution, as well as the risk of developing vari

Endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity, according to the outcomes from a comparative study, ‘Endoscopic Sleeve Gastroplasty Versus Oral Semaglutide for Obesity: A Real World Comparative Study’, presented at the European Society of Gastrointestinal Endoscopy (ESGE) Days 2026. Endoscopic sleeve gastroplasty is a minimally invasive endoscopic procedure that reduces gastric

Changes in gut microbiota after bariatric surgery are strongly linked to altered metabolic health and sustained improvement in type 2 diabetes, according to a study led by researchers at the University of Gothenburg. Bariatric surgery is an effective treatment for obesity and type 2 diabetes, but patient outcomes vary widely. The current study, published in Nature Metabolism, suggests that the variations are partly explained by differences in how the composition of gut bacter

The number of metabolic and bariatric surgery procedures in the United States dropped below 200,000 in 2024 for the first time since 2020, a more than 20% decline from the prior year, according to research ‘‘Examining trends in the decline of bariatric surgery – an MBSAQIP analysis (Abstract ID: 4730)’, presented at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery. Tyler Cohn “After years of steady growth, the number of metabolic and b

Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego find that GLP-1 prescriptions have grown exponentially from less than 4,600 prescriptions in 2018 to more than 1.4 million in 2025 - according to a new real-world analysis ‘Trends of bariatric surgery utilization in patients with severe obesity in the era of GLP-1 use for weight loss (Abstract ID: 4393)’ - presented at the annual scient

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to research, ‘Bariatric surgery effectiveness after glp-1 agonist weight loss (abstract id: 4149)’, presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery. “Patients are increasingly having surgery after GLP-1 therapy,